Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections

被引:129
作者
Takemura, Nobuyuki [1 ]
Saiura, Akio [1 ]
Koga, Rintaro [1 ]
Arita, Junichi [1 ]
Yoshioka, Ryuji [1 ]
Ono, Yoshihiro [1 ]
Hiki, Naoki [1 ]
Sano, Takeshi [1 ]
Yamamoto, Junji [2 ]
Kokudo, Norihiro [3 ]
Yamaguchi, Toshiharu [1 ]
机构
[1] Ariake Hosp, Japanese Fdn Canc Res, Inst Canc, Dept Surg Gastroenterol,Koto Ku, Tokyo 1358550, Japan
[2] Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 359, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Surg, Div Hepatobiliarypancreat Surg, Tokyo, Japan
关键词
Gastric cancer liver metastasis (GLM); Prognosis; Liver resection; HEPATIC RESECTION; COLORECTAL-CANCER; CURATIVE RESECTION; PROGNOSTIC-FACTORS; PHASE-III; SURVIVAL; CHEMOTHERAPY; RECURRENCE; SURGERY; MODEL;
D O I
10.1007/s00423-012-0959-z
中图分类号
R61 [外科手术学];
学科分类号
100210 [外科学];
摘要
The indication for hepatectomy in cases of gastric cancer liver metastases (GLM) remains unclear and it remains controversial whether surgical resection is beneficial for GLM. The objective of this retrospective study was to clarify the indications for and benefit of hepatectomy for GLM. Seventy-three patients underwent hepatectomies for GLM from January 1993 to January 2011. Macroscopically complete (R0 or R1) resection was achieved in 64 patients. Among them, 32 patients underwent synchronous hepatectomy with gastrectomy and the remaining 32 patients underwent metachronous hepatectomy. Repeat hepatectomy was done in 14 patients for resectable intrahepatic recurrences. Clinicopathological factors were evaluated by univariate and multivariate analyses among patients who received macroscopically complete resection for those affecting survival. The overall 1-, 3-, and 5-year survival rates after macroscopically complete (R0 or R1) liver resection (n = 64) for GLM were 84, 50, and 37 %, respectively, with a median survival of 34 months. Univariate analysis identified serosal invasion of the primary gastric cancer and blood transfusions during surgery as poor prognosis indicators. By multivariate analysis, serosal invasion of the primary gastric cancer and larger hepatic tumor (> 5 cm in diameter) were found to be independent indicators of poor prognosis. GLM patients with the maximum diameter of hepatic tumors of < 5 cm and without serosal invasion of the primary gastric cancer are the best candidate for hepatectomy.
引用
收藏
页码:951 / 957
页数:7
相关论文
共 45 条
[1]
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[2]
Hepatic resection for noncolorectal nonendocrine liver Metastases - Analysis of 1452 patients and development of a prognostic model [J].
Adam, Rene ;
Chiche, Laurence ;
Aloia, Thomas ;
Elias, Dominique ;
Salmon, Remy ;
Rivoire, Michel ;
Jaeck, Daniel ;
Saric, Jean ;
Le Treut, Yves Patrice ;
Belghiti, Jacques ;
Mantion, Georges ;
Mentha, Gilles .
ANNALS OF SURGERY, 2006, 244 (04) :524-535
[3]
Benefits and limits of hepatic resection for gastric metastases [J].
Ambiru, S ;
Miyazaki, M ;
Ito, H ;
Nakagawa, K ;
Shimizu, H ;
Yoshidome, H ;
Shimizu, Y ;
Nakajima, N .
AMERICAN JOURNAL OF SURGERY, 2001, 181 (03) :279-283
[4]
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[5]
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study [J].
Boku, Narikazu ;
Yamamoto, Seiichiro ;
Fukuda, Haruhiko ;
Shirao, Kuniaki ;
Doi, Toshihiko ;
Sawaki, Akira ;
Koizumi, Wasaburo ;
Saito, Hiroshi ;
Yamaguchi, Kensei ;
Takiuchi, Hiroya ;
Nasu, Junichiro ;
Ohtsu, Atsushi .
LANCET ONCOLOGY, 2009, 10 (11) :1063-1069
[6]
Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases [J].
Cheon, S. H. ;
Rha, S. Y. ;
Jeung, H. -C. ;
Im, C. -K. ;
Kim, S. H. ;
Kim, H. R. ;
Ahn, J. B. ;
Roh, J. K. ;
Noh, S. H. ;
Chung, H. C. .
ANNALS OF ONCOLOGY, 2008, 19 (06) :1146-1153
[7]
Trends in long-term survival following liver resection for hepatic colorectal metastases [J].
Choti, MA ;
Sitzmann, JV ;
Tiburi, MF ;
Sumetchotimetha, W ;
Rangsin, R ;
Schulick, RD ;
Lillemoe, KD ;
Yeo, CJ ;
Cameron, JL .
ANNALS OF SURGERY, 2002, 235 (06) :759-765
[8]
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. [J].
Cunningham, David ;
Okines, Alicia F. C. ;
Ashley, Sue .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (09) :858-859
[9]
Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis An International Multi-Institutional Analysis of 1669 Patients [J].
de Jong, Mechteld C. ;
Pulitano, Carlo ;
Ribero, Dario ;
Strub, Jennifer ;
Mentha, Gilles ;
Schulick, Richard D. ;
Choti, Michael A. ;
Aldrighetti, Luca ;
Capussotti, Lorenzo ;
Pawlik, Timothy M. .
ANNALS OF SURGERY, 2009, 250 (03) :440-448
[10]
Gastric cancer: D2 dissection or low maruyama index-based surgery - a debate [J].
Douglass, Harold O., Jr. ;
Hundahl, Scott A. ;
Macdonald, John S. ;
Khatri, Vijay P. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (01) :133-+